Drug Discovery

Xenogen enters into agreement for real-time in vivo imaging technology

Published in Cancer Weekly, December 17th, 2002

Xenogen Corp. announced that it has entered into an agreement with Millennium Pharmaceuticals, Inc., (MLNM) in which Millennium will obtain access to Xenogen's proprietary real-time in vivo imaging technology platform for its oncology program.

The technology is expected to enhance the efficiency of Millennium's drug discovery efforts.

Under the terms of the agreement, Millennium is licensed to practice Xenogen's real-time in vivo imaging technology and will purchase Xenogen's IVIS Imaging System and Living Image software package for oncology applications. Millennium also has options to purchase other elements of Xenogen's technology platform: ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-12-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry